Skip to content

Understanding Pain Mechanisms in Knee Osteoarthritis

Unknown statusNot applicableNCT05561010
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

UP-KNEE study is a feasibility, double-blind, placebo-controlled randomised parallel study in participants with radiographically defined knee OA, and with self-reported chronic knee pain.

Study details

Official title
Is There a Difference in the Analgesic Response to Intra-articular Bupivacaine Injection in People With Knee Osteoarthritis Pain With or Without Central Sensitisation?: a Feasibility Randomised Controlled Trial
Interventions
  • Drug: Intra-articular injection of bupivacaine in the knee joint
  • Drug: Intra-articular injection of placebo in the knee joint
Sponsor
Nottingham University Hospitals NHS Trust
Collaborators
University of Nottingham; Versus Arthritis; Aalborg University
Start date
2022-10
Primary completion
2023-03
Sex
All
Age range
from 45 Years
Results posted
No results posted in this snapshot
Total sites listed
0

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Radiographically defined OA knee changes (K/L \> 2); * Must have self-reported knee pain (measuring at least 30 mm to 80 mm on a 100 mm VAS for rest, use or night pain); * Able to give informed consent; * Aged 45 years and older; * All genders; * Able to perform the six-minute walk test. Exclusion Criteria: * Aged less than 45 years; * Breastfeeding or pregnancy; * Not having the capacity to consent; * Non-English speakers; * Major medical, neurological and psychiatric co-morbidities; * Hip OA (ipsilateral or contralateral); * Fibromyalgia; * Sensory dysfunctional illness; * Chronic pain conditions other than OA; * Presence of local or systemic infection or suspicion of infection in the knee joint, overlying soft tissue or elsewhere; * History of septic arthritis in the knee to be injected; * Acute haemarthrosis in the joint to be injected; * Recent trauma within 72 hours; * Prosthetic joint; * Presence of broken skin or rash over the area to be injected; * Severe coagulopathy (can take aspirin or anti-platelets inhibitors such as clopidogrel); * Any anti-coagulant therapy (e.g. warfarin); * Severe liver disease or severe kidney disease; * Known hypersensitivity, allergy or intolerance to local anaesthetic / bupivacaine; * Recently taken other medicines containing local anaesthetic / bupivacaine within 1 month; * Surgery planned within 3 months of entry to study; * Neuropathic pain medications such as opioid analgesics, antiepileptic drugs such as pregabalin / gabapentin, and tricyclic antidepressants such as amitriptyline when taken for neuropathic pain treatment; * Current or recent intake centrally-active medication (e.g. have recently taken monoamine oxidase inhibitor (MAOI)); * Complete heart block; * The presence of any contraindication for MRI.

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05561010